Pozen, Inc. (POZN) Submits Full Response To FDA Approvable Letter For Trexima(TM)
11/9/2006 11:20:12 AM
CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN) today announced the submission of the full response to the Approvable Letter for Trexima™, the proposed brand name for the combination of sumatriptan succinate, formulated with RT Technology™, and naproxen sodium, in a single tablet for the acute treatment of migraine to the U.S. Food and Drug Administration (FDA). The FDA will have up to six months to review the information contained in the full response.
comments powered by